Search
Brexucabtagene autoleucel
go.drugbank.com/drugs/DB15699ApprovedInvestigational[L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma … Mantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant.
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnOn September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082] … [A32080] Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO.
Categories: Compounds used in a research, industrial, or household settingElbasvir
go.drugbank.com/drugs/DB11574Approved[A19626] In a computational target-based drug repurposing investigation published in April 2020, elbasvir was predicted to bind stably and preferentially to three proteins necessary for viral replication … grazoprevir] are used with or without [ribavirin] with the intent to cure, or achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% for genotype 1 and 97% and 100%
Mixtures: ZEPATIER 50 MG/100 MG FİLM KAPLI TABLET, 28 ADETGimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalThe main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … It functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408].
Synonyms: Ts-1 (TN)Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalFood and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). … The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.
Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.
Mixtures: EURARTESIM 320 MG/40 MG FILM COATED TABLETS, D-ARTEPPRimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Categories: M2 Protein Inhibitors, Influenza A M2 Protein InhibitorCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnIts market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].
Difluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]
Mixtures: TRODERM 10 MG/G+1 MG/G KREM ,15 G, TİNAGEN 1 MG+10 MG/1 G DERİ KREMİ, 15 GProducts: NERIFORTE POMAD, 10 G, TEMETEX %01 KREM, 10 GLevorphanol
go.drugbank.com/drugs/DB00854ApprovedA narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.